Forum

Events

Partner Content

Last year we told you that the cell and gene industry would be worth $9 - $14 billion by 2026. We were wrong.

Oncology

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.